Edwards Lifesciences Co. (NYSE:EW) Receives $79.19 Consensus Target Price from Brokerages

Shares of Edwards Lifesciences Co. (NYSE:EW) have been given a consensus recommendation of “Hold” by the twenty-six research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $79.19.

Several equities analysts have commented on the stock. Piper Sandler dropped their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Robert W. Baird decreased their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Finally, Barclays upped their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd.

Edwards Lifesciences Stock Down 0.9 %

Shares of NYSE EW opened at $70.38 on Monday. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a market capitalization of $41.51 billion, a price-to-earnings ratio of 10.16, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The business has a 50-day moving average of $72.45 and a two-hundred day moving average of $69.30.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,000 shares of company stock valued at $547,430. 1.29% of the stock is owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. Harbor Capital Advisors Inc. boosted its holdings in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares during the last quarter. Nordea Investment Management AB raised its holdings in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in shares of Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Finally, Avanza Fonder AB purchased a new position in Edwards Lifesciences in the fourth quarter valued at approximately $4,845,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.